NVIV appears quite confident not only in the HUD being granted shortly but the actual 5 patient human implant trials being well underway in a matter of months as well.
Clearly, NVIV feels they are right there in terms of approval for both. The whole ball of wax.
[b]“We’ll continue what we started at the 2012 Summit, fostering a productive exchange of ideas between InVivo scientists and neurotrauma researchers with the objective of furthering the development of treatments for SCI and other neurotrauma conditions,” said InVivo CEO Frank Reynolds. Since the last Summit, we’ve been focused on advancing our scaffolding device into a first-in-man clinical trial. [color=red]By the 2013 Summit, we expect to have the clinical study underway, [/color]so the Summit will focus on our growing portfolio of hydrogel technologies.”[/b]